Choosing the right competent cells for every cloning and protein expression challenge

Selecting the right competent cells can have a significant impact on the success of cloning, library construction and protein expression experiments underpinning drug discovery. Lucigen has developed a comprehensive portfolio of chemically competent and electrocompetent E. coli strains designed to address challenges ranging from routine cloning and recombinant protein production to CRISPR library generation, BAC cloning and phage display. By providing application-specific strains with high transformation efficiencies and enhanced plasmid stability, Lucigen helps researchers maximise yields, preserve library stability and reduce time spent troubleshooting experimental workflows.

Routine cloning and library construction

For everyday cloning applications, Lucigen's E. cloni® range provides a reliable alternative to standard cloning strains such as DH5α™, DH10B™, JM109, TOP10 and XL1-Blue. These cells are engineered to deliver high transformation efficiencies while improving recombinant yields and cloning reliability.

Key advantages include:

• High transformation efficiencies across both chemical and electrocompetent formats
• Optimised strains for routine cloning, difficult targets and high-complexity libraries
• Blue/white screening capability
• Phage T1 resistance and reduced recombination activity for greater plasmid stability
• Direct replacement for commonly used cloning strains

Researchers constructing large or highly diverse libraries can choose from ELITE and SUPREME strains, while CLASSIC and chemically competent formats provide an economical solution for routine molecular cloning.

Streamlining protein expression workflows

Protein expression projects often require movement of plasmids between cloning and expression strains, adding time and complexity to workflows. Lucigen's E. cloni EXPRESS BL21 (DE3) cells help simplify this process by combining high transformation efficiency with strong protein expression performance.

Benefits include:

• High protein expression levels
• Transformation efficiencies exceeding 5x10⁹ cfu/µg
• Compatibility with T7 promoter-based expression systems
• Elimination of plasmid transfer steps between cloning and expression strains

For applications requiring tighter regulation of expression, HI-Control™ strains incorporate a constitutive lacI repressor, helping minimise leaky expression and improve yields for proteins that may be difficult to express.

Tackling toxic and difficult-to-express proteins

Not every recombinant protein behaves well in a standard BL21 background. Membrane proteins, toxic proteins and other challenging targets can place significant stress on host cells, reducing expression levels and plasmid stability.

Lucigen's OverExpress™ C41 (DE3) and C43 (DE3) strains were developed specifically to address these challenges. These cells stabilise toxic plasmids and enable expression of a broader range of proteins without the need to re-clone into alternative systems.

Key benefits include:

• Improved expression of membrane and toxic proteins
• Increased soluble protein yields
• Stabilisation of problematic constructs
• Availability in both chemical and electrocompetent formats
• Compatibility with T7 promoter-based vectors

Reducing endotoxin at the source

For researchers producing proteins or plasmids destined for mammalian systems, endotoxin contamination can create significant downstream challenges.

ClearColi® BL21 (DE3) cells offer a different approach by addressing the problem during expression rather than relying on post-production endotoxin removal. These cells contain a genetically modified lipopolysaccharide that does not trigger a mammalian endotoxic response.

Applications include:

• Immunogenicity studies
• Cytokine assays
• Toxicity testing
• Therapeutic protein development
• Production of membrane and lipid-binding proteins

By reducing endotoxin at the source, ClearColi cells can help minimise false-positive results and simplify downstream processing.

Supporting advanced library construction

Some applications place exceptional demands on competent cells, requiring maximum transformation efficiency, construct stability and the ability to maintain library diversity throughout the workflow. For these more specialised applications, Lucigen offers purpose-built strains optimised for CRISPR and lentiviral library construction, bacterial artificial chromosome (BAC) cloning and phage display, helping researchers tackle complex projects with confidence.

CRISPR and lentiviral library cloning

Endura™ competent cells are optimised for the construction and maintenance of complex CRISPR and lentiviral libraries. Recommended in GeCKO library protocols, these cells provide exceptional transformation efficiencies and help preserve library diversity.

Highlights include:

• Suitable for CRISPR guide RNA and lentiviral libraries
• Available in chemical and electrocompetent formats
• High DNA yields
• Transformation efficiencies up to 1x10¹⁰ cfu/µg in electrocompetent formats

BAC cloning and large DNA constructs

Working with large inserts requires specialist host strains capable of maintaining construct integrity while supporting efficient transformation.

Lucigen's BAC-Optimised cell range has been developed specifically for BAC library construction, large construct transformation and copy number amplification.

Benefits include:

• High transformation efficiencies for very large DNA constructs
• Optimised DNA yields
• Support for BAC library construction and screening
• On-demand copy number amplification for BAC vectors

Phage display library generation

Library diversity is critical for successful phage display screening. Lucigen's TG1, SS320, ER2738 and MC1061 F- electrocompetent strains deliver some of the highest transformation efficiencies available for phage display applications.

Researchers can select from amber suppressor and non-amber suppressor strains depending on their workflow requirements, enabling the generation of larger and more diverse libraries to accelerate discovery.

Selecting the right strain for your application

Whether you are performing routine cloning, expressing challenging proteins, generating a CRISPR library or constructing large BAC clones, Lucigen offers a competent cell solution tailored to the task. By matching the host strain to the application, researchers can improve transformation success, maximise yields and spend less time troubleshooting experimental bottlenecks.

With specialised strains available for virtually every cloning and expression challenge, Lucigen's competent cell portfolio helps ensure your next transformation starts with the best possible foundation.

Explore our full range of drug discovery solutions for support at every step of the workflow.